Hoyoung Huh MD/PhD is a Silicon Valley-based entrepreneur and investor driven by innovative science, creative collaborations and impact investing. Hoyoung is a global leader in healthcare and technology-based businesses, having been involved in formation/growth of over 20 innovative companies. He is the Founder of Hannol Ventures, pH Pharma and Healthcare & Humanity Foundation. Currently, he serves as Chairman/CEO of pH Pharma, Chairman of Geron Corporation (NASDAQ: GERN), CytomX Therapeutics (NASDAQ:CTMX), and Board Director of AntriaBio (OTC:ANTB) and Shared-X in Peru.
Previously, Hoyoung was CEO of BiPar Sciences, Chairman of Epizyme (NASDAQ:EPZM), Board Director of Facet Biotech (NASDAQ:FACT), Nektar Therapeutics (NASDAQ:NKTR), Addex Therapeutics (SWISS:ADDX) and EOS, S.p.A (Milano, Italy). Earlier in his career, Dr. Huh was a Partner at McKinsey & Company, where he was a leader in the healthcare and technology sectors based in Silicon Valley, New York and Asia.
Hoyoung is a frequent speaker on innovation, entrepreneurship and governance, including presentations at the World Economic Forum, Stanford Business School and Cleveland Clinic. His not-for-profit focus include global health and music, formerly serving as board member for SF Jazz, Resurge International and Berklee School of Music.
Hoyoung holds M.D. from Cornell University, Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and A.B. from Dartmouth College, and Certification in Board Governance from Stanford Law School.